{"id":"placebo-docetaxel","safety":{"commonSideEffects":[{"rate":"75–80","effect":"Neutropenia"},{"rate":"50–60","effect":"Anemia"},{"rate":"25–35","effect":"Thrombocytopenia"},{"rate":"20–30","effect":"Peripheral neuropathy"},{"rate":"50–75","effect":"Alopecia"},{"rate":"30–40","effect":"Nausea/vomiting"},{"rate":"30–40","effect":"Diarrhea"},{"rate":"40–50","effect":"Fatigue"},{"rate":"2–5","effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel binds to beta-tubulin and stabilizes microtubules, preventing their depolymerization during cell division. This disruption of the mitotic spindle causes cells to arrest in the G2/M phase of the cell cycle and undergo apoptosis. It is a semi-synthetic taxane derived from the Pacific yew tree.","oneSentence":"Docetaxel is a microtubule-stabilizing agent that prevents microtubule disassembly, leading to cell cycle arrest and apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:18.008Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Non-small cell lung cancer"},{"name":"Prostate cancer"},{"name":"Gastric cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT05116189","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-12-13","conditions":"Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms","enrollment":643},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT07246863","phase":"PHASE2","title":"Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC","status":"RECRUITING","sponsor":"CatalYm GmbH","startDate":"2025-10-07","conditions":"Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor","enrollment":131},{"nctId":"NCT07109817","phase":"PHASE2","title":"Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-03","conditions":"Breast Cancer, Peripheral Neuropathy","enrollment":116},{"nctId":"NCT04784715","phase":"PHASE3","title":"Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-04-26","conditions":"Breast Cancer; HER2-positive; Metastatic","enrollment":1157},{"nctId":"NCT07361484","phase":"PHASE3","title":"Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)","status":"NOT_YET_RECRUITING","sponsor":"BeyondSpring Pharmaceuticals Inc.","startDate":"2026-06-01","conditions":"Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance","enrollment":442},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT03199885","phase":"PHASE3","title":"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-05","conditions":"Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma","enrollment":190},{"nctId":"NCT04592913","phase":"PHASE3","title":"Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-11-17","conditions":"Gastrointestinal Neoplasms, Esophagogastric Junction","enrollment":957},{"nctId":"NCT05114720","phase":"PHASE3","title":"Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-11-11","conditions":"Breast Cancer","enrollment":559},{"nctId":"NCT02799602","phase":"PHASE3","title":"Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-11-30","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":1306},{"nctId":"NCT01358877","phase":"PHASE3","title":"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-08","conditions":"Breast Cancer","enrollment":4804},{"nctId":"NCT01927744","phase":"PHASE2","title":"Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-12-16","conditions":"Head and Neck Cancer","enrollment":55},{"nctId":"NCT01933932","phase":"PHASE3","title":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2013-09-25","conditions":"Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV","enrollment":510},{"nctId":"NCT06615752","phase":"PHASE1, PHASE2","title":"Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients","status":"RECRUITING","sponsor":"Charles Drew University of Medicine and Science","startDate":"2026-03","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC)","enrollment":99},{"nctId":"NCT03740165","phase":"PHASE3","title":"Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-18","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms","enrollment":1367},{"nctId":"NCT04025879","phase":"PHASE3","title":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-11-05","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":461},{"nctId":"NCT00532155","phase":"PHASE3","title":"A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09","conditions":"Carcinoma, Non Small Cell Lung","enrollment":913},{"nctId":"NCT03588091","phase":"PHASE3","title":"Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-07-24","conditions":"HER2-positive Breast Cancer","enrollment":355},{"nctId":"NCT04725188","phase":"PHASE2","title":"Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-04-20","conditions":"Metastatic Non Small Cell Lung Cancer","enrollment":255},{"nctId":"NCT03834506","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-05-02","conditions":"Prostatic Neoplasms","enrollment":1030},{"nctId":"NCT05712694","phase":"PHASE3","title":"Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)","status":"RECRUITING","sponsor":"Polaris Group","startDate":"2023-11-29","conditions":"Soft Tissue Sarcoma","enrollment":300},{"nctId":"NCT04102124","phase":"PHASE2","title":"A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-04-08","conditions":"Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":20},{"nctId":"NCT04100018","phase":"PHASE3","title":"A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-02-06","conditions":"Prostate Cancer","enrollment":1030},{"nctId":"NCT04634877","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-01-10","conditions":"Endometrial Neoplasms","enrollment":990},{"nctId":"NCT06928389","phase":"PHASE3","title":"Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Akeso","startDate":"2025-06","conditions":"Non-Small Cell Lung Cancer","enrollment":536},{"nctId":"NCT05508347","phase":"PHASE2","title":"Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2022-04-20","conditions":"Nasopharyngeal Carcinoma","enrollment":170},{"nctId":"NCT02288247","phase":"PHASE3","title":"A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2014-12-01","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":688},{"nctId":"NCT05137067","phase":"PHASE2","title":"A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.","status":"COMPLETED","sponsor":"Optimal Health Research","startDate":"2021-01-20","conditions":"Breast Cancer, Lung Cancer, Prostate Cancer","enrollment":90},{"nctId":"NCT03851640","phase":"PHASE3","title":"A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).","status":"RECRUITING","sponsor":"Hinova Pharmaceuticals Inc.","startDate":"2019-04-12","conditions":"MCRPC","enrollment":417},{"nctId":"NCT02231164","phase":"PHASE3","title":"LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2014-10-14","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":12},{"nctId":"NCT02802423","phase":"PHASE1, PHASE2","title":"Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.","status":"NOT_YET_RECRUITING","sponsor":"BioLite, Inc.","startDate":"2026-01-01","conditions":"Triple Negative Breast Cancer","enrollment":44},{"nctId":"NCT05348577","phase":"PHASE3","title":"Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-03-25","conditions":"Prostate Cancer","enrollment":1035},{"nctId":"NCT05922345","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-06-08","conditions":"Non-small Cell Lung Cancer","enrollment":518},{"nctId":"NCT04916613","phase":"PHASE3","title":"ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2022-04-19","conditions":"Prostate Cancer Metastatic","enrollment":300},{"nctId":"NCT06141226","phase":"PHASE2","title":"Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-12","conditions":"Non-small-cell Lung Cancer","enrollment":148},{"nctId":"NCT03102606","phase":"PHASE3","title":"Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3","status":"COMPLETED","sponsor":"BeyondSpring Pharmaceuticals Inc.","startDate":"2018-05-29","conditions":"Chemotherapy-induced Neutropenia","enrollment":105},{"nctId":"NCT01256359","phase":"PHASE2","title":"Docetaxel With or Without AZD6244 in Melanoma","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-10","conditions":"Melanoma","enrollment":83},{"nctId":"NCT01064479","phase":"PHASE2","title":"Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-02-05","conditions":"Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity","enrollment":123},{"nctId":"NCT04907227","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-09-23","conditions":"Prostatic Neoplasms","enrollment":81},{"nctId":"NCT04158440","phase":"PHASE3","title":"Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-04-07","conditions":"Stage II-III Non-small Cell Lung Cancer","enrollment":501},{"nctId":"NCT06492941","phase":"PHASE3","title":"A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-08-12","conditions":"Advanced Pancreatic Cancer","enrollment":142},{"nctId":"NCT02889666","phase":"PHASE1","title":"A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2008-01","conditions":"Recurrent Non-small Cell Lung Cancer","enrollment":500},{"nctId":"NCT01120184","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-07-31","conditions":"Breast Cancer","enrollment":1095},{"nctId":"NCT05627752","phase":"PHASE2, PHASE3","title":"Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2024-06-01","conditions":"Prostate Cancer, Castrate Resistant Prostate Cancer","enrollment":120},{"nctId":"NCT04171284","phase":"PHASE3","title":"SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Sinocelltech Ltd.","startDate":"2019-10-22","conditions":"Squamous-cell Non-Small-cell Lung Cancer","enrollment":188},{"nctId":"NCT05427383","phase":"PHASE2, PHASE3","title":"KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy","status":"RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2022-04-07","conditions":"Stomach Cancer","enrollment":286},{"nctId":"NCT01972217","phase":"PHASE2","title":"Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-04-01","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":158},{"nctId":"NCT01750281","phase":"PHASE2","title":"Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-12-18","conditions":"Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV","enrollment":212},{"nctId":"NCT03761225","phase":"PHASE3","title":"Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"AB Science","startDate":"2014-09","conditions":"Metastatic Castrate Resistant Prostate Cancer","enrollment":714},{"nctId":"NCT02870699","phase":"NA","title":"Efficacy of Evonail® Solution in the Prevention of Nail Damage Induced by Docetaxel in Patients With Breast Cancer.","status":"COMPLETED","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2011-10","conditions":"Breast Carcinoma","enrollment":50},{"nctId":"NCT01485861","phase":"PHASE1, PHASE2","title":"Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-01-11","conditions":"Prostate Cancer","enrollment":298},{"nctId":"NCT03626545","phase":"PHASE3","title":"Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-01-23","conditions":"Non-Small-Cell Lung","enrollment":245},{"nctId":"NCT02426125","phase":"PHASE3","title":"A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-07-13","conditions":"Urothelial Carcinoma","enrollment":530},{"nctId":"NCT02516670","phase":"PHASE2","title":"Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-06-20","conditions":"Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer","enrollment":50},{"nctId":"NCT02586025","phase":"PHASE3","title":"Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-14","conditions":"Breast Cancer","enrollment":329},{"nctId":"NCT05834413","phase":"NA","title":"Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2023-05-01","conditions":"Lung Cancer","enrollment":367},{"nctId":"NCT04863248","phase":"PHASE2","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)","status":"TERMINATED","sponsor":"G1 Therapeutics, Inc.","startDate":"2021-04-30","conditions":"Metastatic Non-Small Cell Lung Cancer, NSCLC, Lung Cancer","enrollment":10},{"nctId":"NCT05698186","phase":"PHASE3","title":"Thero2-01S22 in HER2-positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Institut de cancérologie Strasbourg Europe","startDate":"2023-05-15","conditions":"HER2-positive Breast Cancer","enrollment":320},{"nctId":"NCT00849667","phase":"PHASE3","title":"Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse","status":"TERMINATED","sponsor":"Morphotek","startDate":"2009-04-16","conditions":"Ovarian Cancer","enrollment":1100},{"nctId":"NCT03863223","phase":"PHASE3","title":"A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-04-22","conditions":"Metastatic Breast Cancer","enrollment":590},{"nctId":"NCT02504489","phase":"PHASE3","title":"Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC","status":"COMPLETED","sponsor":"BeyondSpring Pharmaceuticals Inc.","startDate":"2015-12","conditions":"Non-Small Cell Lung Cancer","enrollment":559},{"nctId":"NCT00966914","phase":"PHASE3","title":"Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin","status":"COMPLETED","sponsor":"BioNumerik Pharmaceuticals, Inc.","startDate":"2010-04","conditions":"Non-small Cell Lung Cancer","enrollment":540},{"nctId":"NCT02659020","phase":"PHASE1, PHASE2","title":"A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-03-01","conditions":"Soft Tissue Sarcoma","enrollment":310},{"nctId":"NCT02121639","phase":"PHASE1, PHASE2","title":"Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy","status":"COMPLETED","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2014-01-29","conditions":"Prostate Cancer","enrollment":160},{"nctId":"NCT04822961","phase":"PHASE2","title":"Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment","status":"UNKNOWN","sponsor":"Impact Therapeutics, Inc.","startDate":"2021-12-31","conditions":"mCRPC","enrollment":285},{"nctId":"NCT02896855","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-09-13","conditions":"Breast Cancer","enrollment":243},{"nctId":"NCT00703326","phase":"PHASE3","title":"Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-08-06","conditions":"Breast Cancer","enrollment":1144},{"nctId":"NCT03863483","phase":"PHASE2","title":"A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.","status":"UNKNOWN","sponsor":"Xin-Hua Xu","startDate":"2019-03-26","conditions":"Nonsquamous Non-Small Cell Lung Cancer","enrollment":70},{"nctId":"NCT02468739","phase":"PHASE3","title":"Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-05","conditions":"Breast Cancer","enrollment":206},{"nctId":"NCT00134056","phase":"PHASE3","title":"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2006-08","conditions":"Metastatic Cancer, Prostate Cancer","enrollment":1038},{"nctId":"NCT01220128","phase":"PHASE2","title":"Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-04-11","conditions":"Neoplasms, Breast","enrollment":66},{"nctId":"NCT02111577","phase":"PHASE3","title":"Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"SOTIO a.s.","startDate":"2014-05-26","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":1182},{"nctId":"NCT04772287","phase":"PHASE3","title":"Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-03-31","conditions":"Non Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT03294577","phase":"PHASE3","title":"Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia","status":"UNKNOWN","sponsor":"BeyondSpring Pharmaceuticals Inc.","startDate":"2019-10-23","conditions":"Chemotherapy-induced Neutropenia","enrollment":221},{"nctId":"NCT00738387","phase":"PHASE3","title":"A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-12","conditions":"Non-Small Cell Lung Cancer","enrollment":900},{"nctId":"NCT00466440","phase":"PHASE2","title":"A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-06","conditions":"Prostate Cancer","enrollment":108},{"nctId":"NCT01012297","phase":"PHASE3","title":"Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-11","conditions":"Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma","enrollment":107},{"nctId":"NCT01792050","phase":"PHASE2","title":"Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"NewLink Genetics Corporation","startDate":"2013-02","conditions":"Metastatic Breast Cancer","enrollment":169},{"nctId":"NCT02401542","phase":"PHASE1, PHASE2","title":"Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma","status":"TERMINATED","sponsor":"Rainier Therapeutics","startDate":"2015-06","conditions":"Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases","enrollment":71},{"nctId":"NCT03121833","phase":"PHASE2","title":"Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2017-05-01","conditions":"Soft Tissue Sarcoma, Adult, Stage IIB","enrollment":52},{"nctId":"NCT00567190","phase":"PHASE3","title":"A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-02-12","conditions":"Metastatic Breast Cancer","enrollment":808},{"nctId":"NCT00582582","phase":"PHASE2","title":"Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2002-04","conditions":"Prostate Cancer","enrollment":70},{"nctId":"NCT03656094","phase":"PHASE2","title":"Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2018-11-01","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":98},{"nctId":"NCT03811418","phase":"PHASE3","title":"A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"iOMEDICO AG","startDate":"2019-01","conditions":"Advanced Breast Cancer, HER2-positive Breast Cancer","enrollment":""},{"nctId":"NCT01732549","phase":"PHASE2","title":"A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy","status":"TERMINATED","sponsor":"Ipsen","startDate":"2013-01","conditions":"Metastatic Castrate Resistant Prostate Cancer","enrollment":144},{"nctId":"NCT00771953","phase":"PHASE2","title":"0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2008-11","conditions":"Lung Cancer, Non Small Cell Lung Cancer","enrollment":109},{"nctId":"NCT02721563","phase":"PHASE4","title":"A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC","status":"COMPLETED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2016-02-25","conditions":"Esophageal Neoplasms","enrollment":77},{"nctId":"NCT01703091","phase":"PHASE2","title":"A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-12","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":197},{"nctId":"NCT01168973","phase":"PHASE3","title":"A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Non-Small Cell Lung Cancer","enrollment":1253},{"nctId":"NCT00153803","phase":"PHASE3","title":"Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2005-05","conditions":"Carcinoma, Non-Small-Cell Lung, Non-small Cell Lung Cancer, NSCLC","enrollment":245},{"nctId":"NCT01574716","phase":"PHASE2","title":"Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation","status":"COMPLETED","sponsor":"Morphotek","startDate":"2012-08-07","conditions":"Metastatic Soft Tissue Sarcoma","enrollment":209},{"nctId":"NCT03756064","phase":"NA","title":"Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-08-01","conditions":"Breast Cancer, Neoplasm, Breast, Breast Diseases","enrollment":100},{"nctId":"NCT01695135","phase":"PHASE3","title":"A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-08-09","conditions":"Prostate Neoplasms","enrollment":214},{"nctId":"NCT01707966","phase":"PHASE3","title":"Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2012-09","conditions":"Prostate Cancer","enrollment":47},{"nctId":"NCT02900742","phase":"PHASE3","title":"Clinical Study of Chinese Medicine Plus Chemotherapy Maintenance in Advanced Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2013-03","conditions":"Cancer","enrollment":71},{"nctId":"NCT02766140","phase":"PHASE3","title":"SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2016-06","conditions":"Non Squamous Non Small Cell Lung","enrollment":12},{"nctId":"NCT02364362","phase":"PHASE1","title":"A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-01","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo, docetaxel","genericName":"Placebo, docetaxel","companyName":"Akeso","companyId":"akeso","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel is a microtubule-stabilizing agent that prevents microtubule disassembly, leading to cell cycle arrest and apoptosis in cancer cells. Used for Metastatic breast cancer, Non-small cell lung cancer, Prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}